Mohammed Najeeb Al Hallak

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Asfar Sohail Azmi · 11 shared papers, 2020–2026 · strength 1.69
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. DOI 10.3390/cancers13164161↗
2. Husain Yar Khan · 8 shared papers, 2020–2026 · strength 1.23
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
3. Amro Aboukameel · 8 shared papers, 2020–2026 · strength 1.23
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
4. Ramzi M. Mohammad · 8 shared papers, 2020–2026 · strength 1.23
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. DOI 10.3390/cancers13164161↗
5. Sahar F. Bannoura · 7 shared papers, 2021–2026 · strength 1.18
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
6. Md. Hafiz Uddin · 7 shared papers, 2021–2026 · strength 1.17
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
7. Philip A. Philip · 8 shared papers, 2020–2025 · strength 1.17
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. DOI 10.3390/cancers13164161↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
8. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
9. Bassel F. El‐Rayes · 5 shared papers, 2021–2026 · strength 0.86
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
10. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
11. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
12. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
13. Kay‐Uwe Wagner · 3 shared papers, 2021–2024 · strength 0.48
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor… DOI 10.1101/2023.12.18.572102↗
    • Paper Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. DOI 10.3390/cancers13112777↗
14. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
15. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
16. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
17. Steve H. Kim · 3 shared papers, 2020–2025 · strength 0.36
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
18. Mandana Kamgar · 3 shared papers, 2020–2023 · strength 0.35
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
19. Yiwei Li · 2 shared papers, 2021–2023 · strength 0.34
    • Paper Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. DOI 10.3390/cancers13164161↗
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
20. Anteneh A. Tesfaye · 2 shared papers, 2020 · strength 0.19
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
21. William Adrian Hall · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
22. Susan Tsai · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
23. Irfana Muqbil · 1 shared paper, 2020 · strength 0.09
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
24. Rachel E. Sexton · 1 shared paper, 2020 · strength 0.09
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
25. Maria Diab · 1 shared paper, 2020 · strength 0.09
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.